Merlin Goldman, Lead Technologist

 

Merlin Goldman completed a Masters and PhD in Biochemical Engineering in England with research projects focusing on mammalian cell expression of proteins.  He then moved to Scotland and spent two years as a Research Scientist at PPL Therapeutics characterising the expression of proteins expressed by transgenic sheep.  A move to Serologicals followed and two years as a Fermentation Engineer working on high volume production of monoclonal antibodies. Following a MBA at Edinburgh University and work as a consultant and technical author then moved to Ireland to work for Wyeth validating their new Grange Castle plant, producing Enbrel. After 3 years he returned to London and worked as a consultant and writer prior to taking the role with the Technology Strategy Board. He is Lead Technologist covering the life sciences but focuses on exploitation of the biosciences for economic wealth generation